Rrraum / Shutterstock.com
Pharmaceutical companies have entered into fewer ‘pay-for-delay’ patent settlements since the US Supreme Court said such agreements could violate anti-competition laws, a report has claimed.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Actavis, US Supreme Court, Federal Trade Commission, pay-for-delay, FTC, patent settlement, patent litigation